N/A N=99 Randomized Supportive Care

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Type 1 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT01621776 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2013

Primary outcome: Primary: The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. — 146.69; 143.68; 149.02 mg/dl — p=.971

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Apidra (Drug); Humalog (Drug); Novolog (Drug)
Age: Pediatric · 9+ yrs
Sex: All
Sponsor: University of Florida
Primary completion: Aug 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch.	146.69; 143.68; 149.02	.971
SECONDARY Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner	170.57; 160.96; 153.46	.698
SECONDARY Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast	225.62; 225.46; 208.64	.806

Summary

This study aims to compare the post-meal blood glucose values of two drugs in a "real-world" setting.

Eligibility Criteria

Inclusion Criteria

Diagnosis of type 1 Diabetes
Children and Youth attending Florida Diabetes Camp in DeLand, FL

Exclusion Criteria

only campers participating in sessions I and II are eligible to participate

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01621776). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.